Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Zymeworks Inc. (ZYME)

47.97   -0.29 (-0.6%) 02-14 16:02
Open: 48.32 Pre. Close: 48.26
High: 48.75 Low: 47.12
Volume: 122,954 Market Cap: 2182M
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics, initially focused on the treatment of cancer.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 48.795 - 49.032 49.032 - 49.236
Low: 46.669 - 46.94 46.94 - 47.173
Close: 47.851 - 48.274 48.274 - 48.64

Technical analysis

as of: 2020-02-14 4:34:03 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 61.61     One year: 71.96
Support: Support1: 42.28    Support2: 35.81
Resistance: Resistance1: 52.75    Resistance2: 61.61
Pivot: 46.22
Moving Average: MA(5): 48.42     MA(20): 46.62
MA(100): 38.89     MA(250): 27.80
MACD: MACD(12,26): 0.90     Signal(9): 0.69
Stochastic oscillator: %K(14,3): 82.38     %D(3): 75.28
RSI: RSI(14): 56.74
52-week: High: 52.75  Low: 14.05  Change(%): 211.8
Average Vol(K): 3-Month: 44437  10-Days: 20819

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and BULLISH in mid-long term.
ZYME has closed below upper band by 21.8%. Bollinger Bands are 10.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

The Daily Biotech Pulse: Roche Reports Positive SMA Data Readout, Vir Biotech To Work On Virus Treatment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Jan. 22) 10X Genomics Inc (NASDAQ: TXG ) Abbott Laboratories (NYSE: ABT )(reported strong fourth-quarter results and issued in-line guidance) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Applied Genetic Technologies Corp (NASDAQ: AGTC ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) Bristol-Myers Squibb Co (NYSE: BMY ) Cardiovascular Systems Inc (NASDAQ: CSII ) Dr.Reddy's Laboratories Ltd (NYSE: RDY ) Eli Lilly And Co (NYSE: LLY ) Fortress Biotech (NASDAQ: FBIO ) Horizon Therapeutics PLC (NASDAQ: HZNP )( received FDA nod for its thyroid eye disease drug) Insulet Corporation (NASDAQ: PODD ) Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Nevro Corp (NYSE: NVRO ) Novocure Ltd (NASDAQ: NVCR )(announced coverage in Israel for its Optune in combination with temozolomide for the treatment of newly-diagnosed glioblastoma) Prevail Therapeutics Inc (NASDAQ: PRVL ) Repligen Corporation (NASDAQ: RGEN ) ResMed Inc. (NYSE: RMD ) Selecta Biosciences Inc (NASDAQ: SELB ) SI-Bone Inc (NASDAQ: SIBN ) Soligenix, Inc.

Zymeworks Highlights 2019 Achievements and Announces Corporate Priorities
VANCOUVER, British Columbia--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today highlighted its key accomplishments in 2019 and updated its corporate priorities. Zymeworks also announced multiple clinical program advances for its lead candidates, ZW25 and ZW49. Recent ZW25 and ZW49 Program Advances Zymeworks initiated a Phase 2 clinical trial evaluating ZW25 in combination with Ibrance® (palbociclib), an ora

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  New York Stock Exchange
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 45.48
Shares Float (M) 33.53
% Held by Insiders 7.11
% Held by Institutions 57.43
Shares Short (K) 485
Shares Short P. Month (K)

Stock Financials

EPS -1.830
Book Value (p.s.) 7.870
PEG Ratio
Profit Margin -112.95
Operating Margin -120.65
Return on Assets (ttm) -14.4
Return on Equity (ttm) -26.7
Qtrly Rev. Growth 282.7
Gross Profit (p.s.) -0.081
Sales Per Share
EBITDA (p.s.) -1.433
Qtrly Earnings Growth
Operating Cash Flow (M) 4.61
Levered Free Cash Flow (M) -6.87

Stock Valuations

P/E -26.37
P/E Growth Ratio
P/BV 6.13
P/S 29.97
P/CF 476.11

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.